2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Oxidative Phosphorylation
  5. Oxidative Phosphorylation Inhibitor

Oxidative Phosphorylation Inhibitor

Oxidative Phosphorylation Inhibitors (29):

Cat. No. Product Name Effect Purity
  • HY-184173
    OXPHOS-IN-3
    		Inhibitor
    OXPHOS-IN-3 is a mitochondria-targeted dual OXPHOS/glycolysis inhibitor. OXPHOS-IN-3 exhibits potent antiproliferative activity against pancreatic cancer cells. OXPHOS-IN-3 induces mitochondrial dysfunction, ferroptosis, and immunogenic cell death (ICD). OXPHOS-IN-3 shows potent antitumor activity in pancreatic ductal adenocarcinoma (PDAC) models.
  • HY-181072
    POLRMT-IN-4
    		Inhibitor
    POLRMT-IN-4 is a photoactivated mitochondrial RNA polymerase (POLRMT) inhibitor. POLRMT-IN-4 can be liberated from the photoactivatable prodrug upon irradiation, enables spatiotemporally precise inhibition and localized tissue selectivity. POLRMT-IN-4 disrupts mitochondrial transcription, impairs oxidative phosphorylation, and suppresses cancer cell proliferation. POLRMT-IN-4 can be used in research on various cancers, such as pancreatic cancer.
  • HY-113285
    Ureidopropionic acid
    		Inhibitor 99.95%
    Ureidopropionic acid (3-Ureidopropionic acid) is a selective mitochondrial respiratory chain complex V inhibitor. Ureidopropionic acid induces the production of reactive oxygen species, delayed elevation of intracellular calcium concentration, secondary energy-dependent excitotoxicity and neurodegeneration in neurons. Ureidopropionic acid promotes neuropathological changes by impairing mitochondrial energy metabolism, oxidative stress and excitotoxicity pathways. Ureidopropionic acid can be used in studies related to 3-ureidopropionase deficiency and severe propionic aciduria.
  • HY-W762011
    BDE 47
    		Inhibitor 98.65%
    BDE 47 targets mitochondria, inhibits mitochondrial oxidative phosphorylation (OXPHOS), decreases mitochondrial membrane potential (MMP) and induces apoptosis in embryonic cell. BDE 47 induces the generation of ROS, and activates the JNK signaling pathway. BDE 47 exhibits embryonic developmental toxicity in zebrafish.
  • HY-158421
    MS-L6
    		Inhibitor 99.95%
    MS-L6 is a potent inhibitor of oxidative phosphorylation (OXPHOS) that can acts as electron transport chain complexes I (ETC-I) combining inhibition of NADH oxidation and uncoupling effect.
  • HY-136394
    Diafenthiuron
    		Inhibitor 98.29%
    Diafenthiuron is a thiourea compound commonly used a broad-spectrum insecticide and acaricide. Diafenthiuron disturbs the insect respiratory system by inhibiting the oxidative phosphorylation and mitochondrial ATP synthesis.
  • HY-W011711
    Benzarone
    		Inhibitor 99.67%
    Benzarone is an oral inhibitor of human urate transporter 1 (hURAT1) with an IC50 value of 2.8 μM, and it also acts as an uncoupler of oxidative phosphorylation. Benzarone can cause liver damage and promote cell apoptosis and necrosis. Benzarone can be used to lower serum uric acid levels and for research in vascular diseases.
  • HY-N13254
    Moringa Extract
    		Inhibitor
    Moringa Extract is the extract of Moringa with antioxidative and antibacterial activity. Moringa Extract increases Nrf2 and NQO1 expression, scavenges radicals, reduces oxidative stress, inhibits growth of Staphylococcus aureus and Escherichia coli. Moringa Extract can be used for the research of dietary supplements, cosmetics, and natural water purification.
  • HY-125283
    IM176OUT05
    		Inhibitor 99.43%
    IM176OUT05 (2-Me-Phen hydrochloride), a biguanide, is a mitochondrial OXPHOS inhibitor. IM176OUT0 inhibits mitochondrial electron transport chain (ETC) activity with an IC50 of 3.2 μM. IM176OUT05 activates stem cell metabolism, promotes hair regrowth and increases stemness induction and maintenance during the pluripotent stem cell generation process.
  • HY-113285R
    Ureidopropionic acid (Standard)
    		Inhibitor
    Ureidopropionic acid (Standard) is the analytical standard of Ureidopropionic acid. This product is intended for research and analytical applications. Ureidopropionic acid (3-Ureidopropionic acid) is a selective mitochondrial respiratory chain complex V inhibitor. Ureidopropionic acid induces the production of reactive oxygen species, delayed elevation of intracellular calcium concentration, secondary energy-dependent excitotoxicity and neurodegeneration in neurons. Ureidopropionic acid promotes neuropathological changes by impairing mitochondrial energy metabolism, oxidative stress and excitotoxicity pathways. Ureidopropionic acid can be used in studies related to 3-ureidopropionase deficiency and severe propionic aciduria.
  • HY-161767
    JWJ-01-306
    		Inhibitor
    JWJ-01-306 is a CRBN-recruiting ZBTB11 Molecular Glues degrader. JWJ-01-306 degrades ZBTB11 and reprograms cellular metabolism, thereby reducing the level of Oxidative Phosphorylation and the activity of the tricarboxylic acid cycle. JWJ-01-306 enhances the response of organoids to K-Ras inhibition. JWJ-01-306 inhibits the proliferation of pancreatic ductal adenocarcinoma cells and melanoma cells. JWJ-01-306 can be used in studies related to pancreatic ductal adenocarcinoma and melanoma.
  • HY-159007
    BD-AcAc2
    		Inhibitor
    BD-AcAc2 (R,S-1,3-Butanediol acetoacetate diester) is an orally active, CNS-penetrant antiepileptic agent. BD-AcAc2 inhibits NF-κB, NLRP3 inflammasome, caspase-1/3, pyroptosis, apoptosis, and enhances autophagy. BD-AcAc2 exhibits antioxidant activity by modulating ROS, MDA, SOD, and GSH levels, and alleviates oxidative stress. BD-AcAc2 mitigates chronic colitis, counteracts Dextran Sodium Sulfate (DSS)-induced pathology, protects against central nervous system oxygen toxicity and acute lung injury, and exhibits anti-seizure efficacy. BD-AcAc2 can be used for the research of colitis, sarcopenia, acute lung injury, seizure, and obesity.
  • HY-176775
    TPP-IOA
    		Inhibitor
    TPP-IOA is a cytochrome c peroxidase inhibitor. TPP-IOA inhibits apoptosis by preventing cardiolipin oxidation and cytochrome c release to the cytosol. TPP-IOA disrupts oxidative phosphorylation in isolated mitochondria. TPP-IOA inhibits cell death in SH-SY5Y cells grown in glucose, but not galactose. TPP-IOA causes mitochondrial depolarization and network fragmentation. TPP-lOA mitigates radiation induced death in mice.
  • HY-153156
    R419
    		Inhibitor
    R419 is a Complex I inhibitor. R419 has anti-cancer activity against liver cancer.
  • HY-176284
    OXPHOS-IN-2
    		Inhibitor
    OXPHOS-IN-2 is an orally active OXPHOS inhibitor. OXPHOS-IN-2 exhibits potent inhibitory activity in PC9 (IC50 = 12.3 nM) and Bxpc-3 cells (IC50 = 250 nM in glucose medium, IC50 = 17.5 nM in galactose medium). OXPHOS-IN-2 decreases the NADH/NAD+ ratio and reduces ATP levels. OXPHOS-IN-2 induces tumor cells apoptosis by activating reactive oxygen species (ROS) and downregulating the level of Nrf2. OXPHOS-IN-2 can be used for research on cancer such as non-small cell lung cancer and pancreatic cancer.
  • HY-B1729S1
    Phenoxyethanol-d4
    		Inhibitor
    Phenoxyethanol-d4 is the deuterium labeled Phenoxyethanol. Phenoxyethanol has a broad spectrum of antimicrobial agent. Phenoxyethanol is an uncouple agent in oxidative phosphorylation from respiration and competitively inhibits malate dehydrogenase. Phenoxyethanol is used as a preservative in cosmetic, vaccine, and textile, et al.
  • HY-164445
    STAT3-IN-32
    		Inhibitor
    STAT3-IN-32 is an orally active, selective STAT3 SH2 domain inhibitor with a Kd of 21.3 nM, showing selectivity over STAT1/5. STAT3-IN-32 binds to the STAT3 SH2 domain, blocks Tyr705 and Ser727 phosphorylation, abrogates nuclear transcription and mitochondrial oxidative phosphorylation functions. STAT3-IN-32 inhibits tumor growth in mouse pancreatic cancer xenograft models. STAT3-IN-32 can be used for the research of pancreatic cancer.
  • HY-175673
    LCB-2151
    		Inhibitor
    LCB-2151 (Compound 2), a nucleoside analogue, is an anticancer agent. LCB-2151 disrupts the two primary sources of ATP production (glycolysis and mitochondrial oxidative phosphorylation), reducing the bioenergetic capacity of KRAS-mutated pancreatic cancer cells and inducing ROS formation. LCB-2151 effectively inhibits key enzymes (such as CACT and CPT2) in glycolysis, the TCA cycle and fatty acid β-oxidation. LCB-2151 has significant cytotoxicity and induces cells apoptosis. LCB-2151 can be used for radiation therapy of cancers research.
  • HY-174257
    RCD405
    		Inhibitor
    RCD405 is a bronchodilator. RCD405 exerts relaxant effects by acting directly on human airway smooth muscle (hASM) with an EC50 value of 12 μM for histamine-induced contractions and 45.71 μM for carbachol-induced contractions. RCD405 inhibits cholinergic and histaminergic tone and reduces electrically stimulated (EFS)-induced contractions. RCD405 is promising for research of asthma and chronic obstructive pulmonary disease (COPD).
  • HY-W762011R
    BDE 47 (Standard)
    		Inhibitor
    BDE 47 (Standard) is the analytical standard of BDE 47. This product is intended for research and analytical applications. BDE 47 targets mitochondria, inhibits mitochondrial oxidative phosphorylation (OXPHOS), decreases mitochondrial membrane potential (MMP) and induces apoptosis in embryonic cell. BDE 47 induces the generation of ROS, and activates the JNK signaling pathway. BDE 47 exhibits embryonic developmental toxicity in zebrafish.